Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Status:
RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
Phase:
PHASE2
Details
Lead Sponsor:
Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators:
Regeneron Pharmaceuticals Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden Translational Skin Cancer Research, University Duisburg-Essen